These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 1794940)

  • 1. Treatment of visceral fat obesity.
    Fujioka S; Matsuzawa Y; Tokunaga K; Keno Y; Kobatake T; Tarui S
    Int J Obes; 1991 Sep; 15 Suppl 2():59-65. PubMed ID: 1794940
    [No Abstract]   [Full Text] [Related]  

  • 2. Visceral fat obesity: anthropological and pathophysiological aspects.
    Tarui S; Tokunaga K; Fujioka S; Matsuzawa Y
    Int J Obes; 1991 Sep; 15 Suppl 2():1-8. PubMed ID: 1794929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic improvements associated with a reduction of abdominal visceral fat caused by a new alpha-glucosidase inhibitor, AO-128, in Zucker fatty rats.
    Kobatake T; Matsuzawa Y; Tokunaga K; Fujioka S; Kawamoto T; Keno Y; Inui Y; Odaka H; Matsuo T; Tarui S
    Int J Obes; 1989; 13(2):147-54. PubMed ID: 2663746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Miglitol, α-glycosidase inhibitor, reduces visceral fat accumulation and cardiovascular risk factors in subjects with the metabolic syndrome: a randomized comparable study.
    Shimabukuro M; Higa M; Yamakawa K; Masuzaki H; Sata M
    Int J Cardiol; 2013 Sep; 167(5):2108-13. PubMed ID: 22721642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The alpha-glucosidase inhibitor miglitol affects bile acid metabolism and ameliorates obesity and insulin resistance in diabetic mice.
    Hamada Y; Nagasaki H; Fuchigami M; Furuta S; Seino Y; Nakamura J; Oiso Y
    Metabolism; 2013 May; 62(5):734-42. PubMed ID: 23194643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imino sugar therapy for type 1 Gaucher disease.
    Priestman DA; Platt FM; Dwek RA; Butters TD
    Glycobiology; 2000 Nov; 10(11):iv-vi. PubMed ID: 11221677
    [No Abstract]   [Full Text] [Related]  

  • 7. The treatment of obesity.
    Med Lett Drugs Ther; 1971 Jul; 13(15):61-2. PubMed ID: 5558450
    [No Abstract]   [Full Text] [Related]  

  • 8. Mapping the intestinal alpha-glucogenic enzyme specificities of starch digesting maltase-glucoamylase and sucrase-isomaltase.
    Jones K; Sim L; Mohan S; Kumarasamy J; Liu H; Avery S; Naim HY; Quezada-Calvillo R; Nichols BL; Pinto BM; Rose DR
    Bioorg Med Chem; 2011 Jul; 19(13):3929-34. PubMed ID: 21669536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin resistance in visceral obesity.
    Kissebah AH
    Int J Obes; 1991 Sep; 15 Suppl 2():109-15. PubMed ID: 1794931
    [No Abstract]   [Full Text] [Related]  

  • 10. Improvement of glucose and lipid metabolism associated with selective reduction of intra-abdominal visceral fat in premenopausal women with visceral fat obesity.
    Fujioka S; Matsuzawa Y; Tokunaga K; Kawamoto T; Kobatake T; Keno Y; Kotani K; Yoshida S; Tarui S
    Int J Obes; 1991 Dec; 15(12):853-9. PubMed ID: 1794928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Body composition and metabolic effects of a diet and exercise weight loss regimen on obese, HIV-infected women.
    Engelson ES; Agin D; Kenya S; Werber-Zion G; Luty B; Albu JB; Kotler DP
    Metabolism; 2006 Oct; 55(10):1327-36. PubMed ID: 16979403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. alpha-Glucosidase inhibition in the treatment of diabetes mellitus.
    Dimitriadis G; Raptis S
    Horm Metab Res Suppl; 1992; 26():42-9. PubMed ID: 1490691
    [No Abstract]   [Full Text] [Related]  

  • 13. Obesity and its treatment by diet and exercise.
    Parízková J
    World Rev Nutr Diet; 1993; 72():78-91. PubMed ID: 8506712
    [No Abstract]   [Full Text] [Related]  

  • 14. [Visceral fat obesity].
    Tokunaga K
    Nihon Rinsho; 1995 Jun; 53 Suppl():257-61. PubMed ID: 7563715
    [No Abstract]   [Full Text] [Related]  

  • 15. Amplification of the inhibitory activity of miglitol by monofluorination.
    Prell E; Csuk R
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5673-4. PubMed ID: 19700320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-butyldeoxynojirimycin causes weight loss as a result of appetite suppression in lean and obese mice.
    Priestman DA; van der Spoel AC; Butters TD; Dwek RA; Platt FM
    Diabetes Obes Metab; 2008 Feb; 10(2):159-66. PubMed ID: 18190430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apolipoprotein E-dependent inverse regulation of vertebral bone and adipose tissue mass in C57Bl/6 mice: modulation by diet-induced obesity.
    Bartelt A; Beil FT; Schinke T; Roeser K; Ruether W; Heeren J; Niemeier A
    Bone; 2010 Oct; 47(4):736-45. PubMed ID: 20633710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Obesity. Its medico-surgical treatment].
    Campollo Rivas O
    Rev Gastroenterol Mex; 1994; 59(1):36-45. PubMed ID: 8209151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regional variation in plasminogen activator inhibitor-1 expression in adipose tissue from obese individuals.
    Eriksson P; Van Harmelen V; Hoffstedt J; Lundquist P; Vidal H; Stemme V; Hamsten A; Arner P; Reynisdottir S
    Thromb Haemost; 2000 Apr; 83(4):545-8. PubMed ID: 10780314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The cutoff point of visceral fat area as a goal for improving risk factors of arteriosclerosis in patients with glucose intolerance].
    Nagano M; Sasaki H; Kumagai S
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():417-20. PubMed ID: 15779415
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.